Literature DB >> 26458765

Differential Requirements for IL-17A and IL-22 in Cecal versus Colonic Inflammation Induced by Helicobacter hepaticus.

Peter J Morrison1, Sarah J Ballantyne1, Sandy J Macdonald2, John W J Moore1, David Jenkins1, Jill F Wright3, Lynette A Fouser3, Marika C Kullberg4.   

Abstract

Type 17 helper T-cell cytokines have been implicated in the pathogenesis of inflammatory bowel disease, a chronic condition affecting the gastrointestinal tract, but information regarding their contribution to pathology in different regions of the gut is lacking. By using a murine model of bacteria-induced typhlocolitis, we investigated the role of IL-17A, IL-17F, and IL-22 in cecal versus colonic inflammation. Cecal, but not colonic, pathology in C57BL/6 mice inoculated with Helicobacter hepaticus plus anti-IL-10 receptor (IL-10R) monoclonal antibody was exacerbated by co-administration of anti-IL-17A monoclonal antibody, suggesting a disease-protective role for IL-17A in the cecum. In contrast, anti-IL-17F had no effect on H. hepaticus-induced intestinal pathology. Neutralization of IL-22 prevented the development of colonic, but not cecal, inflammation in H. hepaticus-infected anti-IL-10R-treated mice, demonstrating a pathogenic role for IL-22 in the colon. Analysis of transcript levels revealed differential expression of IL-22R, IL-22 binding protein, and IL-23R between cecum and colon, a finding that may help explain why these tissues respond differently after anti-IL-22 treatment. Analysis of microarray data from healthy human intestine further revealed significant differences in cytokine receptor transcript levels (including IL-22RA1 and IL-23R) in distinct parts of the human gut. Together, our findings demonstrate that individual type 17 helper T-cell cytokines can have proinflammatory or anti-inflammatory effects in different regions of the intestine, an observation that may have implications for interventions against human inflammatory bowel disease.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26458765      PMCID: PMC4729236          DOI: 10.1016/j.ajpath.2015.08.015

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

1.  Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes.

Authors:  S V Kotenko; L S Izotova; O V Mirochnitchenko; E Esterova; H Dickensheets; R P Donnelly; S Pestka
Journal:  J Biol Chem       Date:  2000-10-16       Impact factor: 5.157

2.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

3.  A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.

Authors:  Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho
Journal:  Science       Date:  2006-10-26       Impact factor: 47.728

4.  A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist.

Authors:  W Xu; S R Presnell; J Parrish-Novak; W Kindsvogel; S Jaspers; Z Chen; S R Dillon; Z Gao; T Gilbert; K Madden; S Schlutsmeyer; L Yao; T E Whitmore; Y Chandrasekher; F J Grant; M Maurer; L Jelinek; H Storey; T Brender; A Hammond; S Topouzis; C H Clegg; D C Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 5.  Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.

Authors:  Gregory F Sonnenberg; Lynette A Fouser; David Artis
Journal:  Nat Immunol       Date:  2011-05       Impact factor: 25.606

6.  Genomic structure and inducible expression of the IL-22 receptor alpha chain in mice.

Authors:  A Tachiiri; R Imamura; Y Wang; M Fukui; M Umemura; T Suda
Journal:  Genes Immun       Date:  2003-03       Impact factor: 2.676

7.  IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration.

Authors:  Stephan Brand; Florian Beigel; Torsten Olszak; Kathrin Zitzmann; Sören T Eichhorst; Jan-Michel Otte; Helmut Diepolder; Andreas Marquardt; Wolfgang Jagla; Andreas Popp; Stéphane Leclair; Karin Herrmann; Julia Seiderer; Thomas Ochsenkühn; Burkhard Göke; Christoph J Auernhammer; Julia Dambacher
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-04       Impact factor: 4.052

8.  Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease.

Authors:  Lauren A Zenewicz; George D Yancopoulos; David M Valenzuela; Andrew J Murphy; Sean Stevens; Richard A Flavell
Journal:  Immunity       Date:  2008-12-19       Impact factor: 31.745

9.  Comparison of interleukin-22 and interleukin-10 soluble receptor complexes.

Authors:  Naomi J Logsdon; Brandi C Jones; Kristopher Josephson; Jennifer Cook; Mark R Walter
Journal:  J Interferon Cytokine Res       Date:  2002-11       Impact factor: 2.607

10.  IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease.

Authors:  Kerstin Wolk; Ellen Witte; Ute Hoffmann; Wolf-Dietrich Doecke; Stefanie Endesfelder; Khusru Asadullah; Wolfram Sterry; Hans-Dieter Volk; Bianca Maria Wittig; Robert Sabat
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422

View more
  9 in total

1.  Mutagenicity of Helicobacter hepaticus infection in the lower bowel mucosa of 129/SvEv Rag2-/- Il10-/- gpt delta mice is influenced by sex.

Authors:  Zhongming Ge; Yan Feng; Alexander Sheh; Sureshkumar Muthupalani; Guanyu Gong; Supawadee Chawanthayatham; John M Essigmann; James G Fox
Journal:  Int J Cancer       Date:  2019-05-07       Impact factor: 7.396

2.  Helicobacter hepaticus cytolethal distending toxin promotes intestinal carcinogenesis in 129Rag2-deficient mice.

Authors:  Zhongming Ge; Yan Feng; Lili Ge; Nicola Parry; Sureshkumar Muthupalani; James G Fox
Journal:  Cell Microbiol       Date:  2017-02-20       Impact factor: 3.715

3.  IL-10 Receptor Neutralization-Induced Colitis in Mice: A Comprehensive Guide.

Authors:  Piu Saha; Rachel M Golonka; Ahmed A Abokor; Beng San Yeoh; Matam Vijay-Kumar
Journal:  Curr Protoc       Date:  2021-08

4.  Novel Helicobacter species H.japonicum isolated from laboratory mice from Japan induces typhlocolitis and lower bowel carcinoma in C57BL/129 IL10-/- mice.

Authors:  Zeli Shen; Yan Feng; Sureshkumar Muthupalani; Alexander Sheh; Lenzie E Cheaney; Christian A Kaufman; Guanyu Gong; Bruce J Paster; James G Fox
Journal:  Carcinogenesis       Date:  2016-09-21       Impact factor: 4.944

5.  Interleukin-22 drives nitric oxide-dependent DNA damage and dysplasia in a murine model of colitis-associated cancer.

Authors:  C Wang; G Gong; A Sheh; S Muthupalani; E M Bryant; D A Puglisi; H Holcombe; E A Conaway; N A P Parry; V Bakthavatchalu; S P Short; C S Williams; G N Wogan; S R Tannenbaum; J G Fox; B H Horwitz
Journal:  Mucosal Immunol       Date:  2017-02-15       Impact factor: 7.313

6.  The development of colitis in Il10-/- mice is dependent on IL-22.

Authors:  Dilini C Gunasekera; Jinxia Ma; Vimvara Vacharathit; Palak Shah; Amritha Ramakrishnan; Priyanka Uprety; Zeli Shen; Alexander Sheh; Cory F Brayton; Mark T Whary; James G Fox; Jay H Bream
Journal:  Mucosal Immunol       Date:  2020-01-13       Impact factor: 7.313

7.  Male-Dependent Promotion of Colitis in 129 Rag2-/- Mice Co-Infected with Helicobacter pylori and Helicobacter hepaticus.

Authors:  Zhongming Ge; Lili Ge; Sureshkumar Muthupalani; Yan Feng; James G Fox
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

8.  The Deletion of IL-17A Enhances Helicobacter hepaticus Colonization and Triggers Colitis.

Authors:  Liqi Zhu; Zhihao Wu; Chen Zhu; Jun Yin; Yuzheng Huang; Jie Feng; Quan Zhang
Journal:  J Inflamm Res       Date:  2022-04-29

9.  The Artificial Sweetener Splenda Promotes Gut Proteobacteria, Dysbiosis, and Myeloperoxidase Reactivity in Crohn's Disease-Like Ileitis.

Authors:  Alexander Rodriguez-Palacios; Andrew Harding; Paola Menghini; Catherine Himmelman; Mauricio Retuerto; Kourtney P Nickerson; Minh Lam; Colleen M Croniger; Mairi H McLean; Scott K Durum; Theresa T Pizarro; Mahmoud A Ghannoum; Sanja Ilic; Christine McDonald; Fabio Cominelli
Journal:  Inflamm Bowel Dis       Date:  2018-04-23       Impact factor: 5.325

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.